A Simplified Regimen to Prevent Nausea and Vomiting Using Netupitant/Palonosetron in Germ Cell Cancer Patients Receiving Chemotherapy

ConditionGerm Cell Cancer

Trial statusNot yet recruiting

Trial phaseEarly Phase 1

Trial typeInterventional

Biological sexAll

Age18+

SponsorOttawa Hospital Research Institute

About this trial

This is a single-site, open-label, randomized pilot feasibility study conducted at The Ottawa Hospital Cancer Centre. A total of 10 participants will be randomized 1:1 to either the experimental or control arm.

The purpose of this study is to evaluate recruitment capability, intervention adherence, data completeness, and safety prior to consideration of a potential future multi-centre randomized trial.

Eligibility criteria

Qualifiers

Diagnosis of germ cell cancer

Indication for outpatient treatment using a standard 5-day cisplatin-based chemotherapy regimen

Disqualifiers

None

Trial design

Treatments tested in this trial

Netupitant/Palonosetron Hydrochloride
Ondansetron (Control)
Aprepitant
Dexamethasone
Olanzapine

Treatment groups

10 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Ottawa Hospital Research Institute

Lead sponsor

Source ClinicalTrials.gov